Biological behaviour of moderate dysplasia--a prospective study
- PMID: 9063015
Biological behaviour of moderate dysplasia--a prospective study
Abstract
The present communication reports the biological behaviour of women with moderate dysplastic lesions of uterine cervix based on a long term prospective study. Two hundred and thirty nine women with moderate dysplasia by cervical cytology who satisfied the criteria for registration were longitudinally followed up at 3 +/- 1 monthly intervals along with age and parity matched controls for a period ranging from 4 to 132 months. The cumulative rate of progression from moderate dysplasia to malignancy (CIS) was observed to be 23.0% at the end of 72 months of follow up with mean transition interval of 24.2 months. Out of 239 cases, 142 women who had more than 24 months of follow up were considered for studying the biological behaviour of the lesion. It was observed that during a follow up of 132 months, 14(9.9%) and 15(10.6%) women progressed to carcinoma in-situ and severe dysplasia respectively. The persistence of lesion was observed in 21(14.8%) women while 11(7.3%) and 81(57.0%) regressed to mild dysplasia and normalcy respectively.
Similar articles
-
Behavior of moderate cervical dysplasia during long-term follow-up.Obstet Gynecol. 1983 May;61(5):609-14. Obstet Gynecol. 1983. PMID: 6835614
-
Is the HSIL subclassification cytologically real and clinically justified?Coll Antropol. 2010 Jun;34(2):395-400. Coll Antropol. 2010. PMID: 20698108
-
[Cervical dysplasia].Vopr Onkol. 1984;30(3):21-8. Vopr Onkol. 1984. PMID: 6710945 Russian.
-
The mode ages of women with cervical dysplasia.Obstet Gynecol. 1993 Sep;82(3):430-4. Obstet Gynecol. 1993. PMID: 8355947 Review.
-
Cervical intraepithelial neoplasia (dysplasia and carcinoma in situ) and early invasive cervical carcinoma.CA Cancer J Clin. 1989 May-Jun;39(3):157-78. doi: 10.3322/canjclin.39.3.157. CA Cancer J Clin. 1989. PMID: 2496898 Review. No abstract available.
Cited by
-
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3.Br J Cancer. 2003 Sep 15;89(6):1062-6. doi: 10.1038/sj.bjc.6601196. Br J Cancer. 2003. PMID: 12966426 Free PMC article. Clinical Trial.
-
Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.Ther Innov Regul Sci. 2021 Jan;55(1):48-55. doi: 10.1007/s43441-020-00189-1. Epub 2020 Jun 22. Ther Innov Regul Sci. 2021. PMID: 32572770